Posted from: Monday, February 01, 2016 - 01:23 PM - Present

Gleevec Now Available As A Generic

January 21, 2016 – Gleevec (imatinib mesylate) a chemotherapy medication indicated to treat chronic myeloid leukemia, manufactured by Novartis Pharmaceuticals, is now available as a generic.  The generic version, manufactured by Sun Pharmaceuticals is significantly less expensive than the brand name counterpart.  This is good news as Gleevec is one of the top specialty medications for BeneCard PBF clients.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Friday, October 18, 2019 - 02:06 AM.